<DOC>
	<DOCNO>NCT01515020</DOCNO>
	<brief_summary>Hypothesis : The use daptomycin treat nosocomial healthcare-associated bacteremia due methicillin-resistant S. aureus ( MRSA ) would increase proportion patient whose blood culture sterilize 72 hour 15 % relative vancomycin would improve treatment safety . Hypothesis : MRSA nosocomial healthcare relate bacteriemia treatment , use daptomycin versus vancomycin would increase 15 % proportion patient sterilize blood culture 72 hour would increase treatment safety . Primary objective : To study efficacy daptomycin compare vancomycin sterilization blood culture 72 hour therapy .</brief_summary>
	<brief_title>Daptomycin Versus Vancomycin Treatment Nosocomial Healthcare-associated MRSA Bacteremia</brief_title>
	<detailed_description>Introduction : Nosocomial and/or healthcare-associated Staphylococcus aureus infection common , serious condition . S. aureus account 20 % case nosocomial bacteremia , associate mortality 20-40 % . This severity due virulence bacterium , age comorbidity patient infection occur . First-line therapy base vancomycin , prevalence methicillin resistance S. aureus ( ~20 % ) still high hospital environment . However bactericidal activity drug slow cause dose-dependent nephrotoxicity . The persistence positive blood culture 72 hour , parameter predictive infection complicate clinical course , see 35 % patient receive vancomycin therapy . Hypothesis : The use daptomycin treat nosocomial healthcare-associated bacteremia due methicillin-resistant S. aureus ( MRSA ) would increase proportion patient whose blood culture sterilize 72 hour 15 % relative vancomycin would improve treatment safety . Primary objective : To study efficacy daptomycin compare vancomycin sterilization blood culture 72 hour therapy . Secondary objective : Clinical cure D14 D28 ; relapse-free clinical bacteriological cure D90 ; mortality D14 , D28 D90 ; treatment duration ( day ) sterilization blood culture ; side effect occurrence treatment , renal insufficiency ; peripheral vein toxicity require placement central venous catheter ; side effect require change study treatment ; duration hospitalization bacteremia ; increase least 2 dilution minimal inhibitory concentration ( MIC ) daptomycin and/or vancomycin first last clinical isolates S. aureus . Methodology : A prospective , multicenter , randomize , open-label study compare daptomycin monotherapy vancomycin monotherapy . Patients randomized nosocomial healthcare-associated infection , blood culture positive Gram-positive cocci cluster , rapid molecular diagnostic test ( GENEXPERT ) confirm presence methicillin-resistant S. aureus . Daptomycin give daily monotherapy ( 10 mg/kg single infusion 30 minute peripheral vein ) . Standard therapy vancomycin monotherapy give intermittent continuous infusion obtain trough concentration 15-20 mg/L plateau concentration 20-25 mg/L , respectively . The treatment duration bacteremia arm 14 day intravenous therapy uncomplicated bacteremias 28 day intravenous therapy complicate bacteremia , define persistent fever positive blood culture 72 h study treatment , secondary septic localization exist enrollment , presence foreign material without sign infection . The duration treatment study reduce patient answer follow criterion : Uncomplicated bacteremia : 10 day treatment instead 14 day : - 2 sterilization blood culture - Patient clinically cure - Visit J14 realize center Complicated bacteremia : 21 day treatment instead 28 day : - 2 sterilization blood culture - Patient clinically cure - Visit J28 realize center In every case , oral relay substitute possible reduction duration treatment study . A blinded study design select two treatment administer differently , due invasive nature continuous infusion pump , primary objective concern microbiological outcome . Patient management clinical monitoring comply usual good clinical practice patient . Visits D14 , D28 D90 necessary . Laboratory monitor comprise daily blood culture sterile culture obtain 2 consecutive day ; full blood count ( FBC ) , serum creatine , CPK treatment , D3 , D7 , D10 D14 , patient receive 28 day treatment , D21 D28 . Where myalgia elevation creatine phosphokinase ( CPK ) &gt; 5 N , isolated elevation CPK &gt; 10 N occurs , treatment daptomycin discontinue clinical laboratory-based monitoring maintain normalization . Number subject require : After 72 hour vancomycin therapy , blood culture still positive 35 % patient . The objective show superiority daptomycin sterilization blood culture 72 hour , margin 15 % ( 80 % versus 65 % ) . With power 80 % type I error rate 5 % , addition 10 % allow unevaluable outcome death 72 hour , number subject require arm 166 ( total = 332 patient ) . Study logistics : Duration study : 2 year ; Enrollment period : 21 month ; Duration patient 's participation : 3 month ; Number participate study site : 15 . Study site choose basis blood culture system use , &gt; 10 methicillin-resistant S. aureus blood culture 2009 possibility set rapid diagnosis trial . A two-person team consist bacteriologist clinician responsible [ screen ] , [ enrollment ] [ ] [ randomization ] [ ] study site . Mean number patient enrol per month per site : 1-5 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Cross Infection</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Methicillin</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients nosocomial and/or healthcareassociated bacteremia Grampositive cocci cluster Confirmed meticillinresistant S. aureus use GeneXpert rapid molecular test Aged 18 year old Who give write consent possible someone his/her family , possible , emergency inclusion Who receive followup entire duration study , i.e . 90 day EXCLUSION CRITERIA : Known allergy vancomycin daptomycin Women pregnant breastfeeding Patients receive vancomycin treatment 48 hour diagnostic blood culture randomization Specific sit infection : pneumonia , meningitis , brain abscess , osteitis , polymicrobial infection Life expectancy consider less 72 hour Severe hepatic impairment ( Child C ) Shortterm intravascular catheter remove immediately EXCLUSION CRITERIA D1 D5 inclusive : Specific site infection : osteitis diagnose D1 D5 inclusive Permanent foreign material infection ( endovascular stent , replacement heart valves joint , pace maker etc . ) remove within 36 hour first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>bacteremia</keyword>
	<keyword>meticillin-resistant Staphylococcus aureus</keyword>
	<keyword>nosocomial infection</keyword>
	<keyword>healthcare-associated infection</keyword>
	<keyword>rapid molecular diagnostic test</keyword>
</DOC>